Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer
Stopped early · Phase 1/Phase 2
Conditions studied: Prostate Cancer
In brief
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving vatalanib together with docetaxel and prednisone may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of vatalanib when given together with docetaxel and prednisone and to see how well they work in treating patients with advanced prostate cancer.
Key facts
- Study ID
- NCT00293371
- Run by
- University of California, San Francisco
- People needed
- 6
- Starts
- 2005-02-01
- Expected to finish
- 2006-09-01
- Last updated by the study team
- 2012-10-11
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- UCSF Comprehensive Cancer Center — San Francisco, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.